Cargando…

Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC

BACKGROUND: Surgery is regarded as the treatment’s cornerstone for early stage and locally advanced non-small cell lung cancer (NSCLC) whenever the tumor is considered resectable. Liquid biopsy is one of the most promising research areas in oncology in the last 10 years, providing a useful non-invas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garitaonaindia, Yago, Aguado-Noya, Ramón, Garcia-Grande, Aranzazu, Cordoba, Mar, Coronado Albi, Maria Jose, Campo Cañaveral, Jose Luis, Calvo, Virginia, Clemente, Mariola Blanco, Álvarez, Ruth, Peñas, Marta, Chara, Luis, Royuela, Ana, Provencio, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413043/ https://www.ncbi.nlm.nih.gov/pubmed/37577300 http://dx.doi.org/10.21037/tlcr-22-827

Ejemplares similares

Cost-effectiveness of diagnostic tests during follow-up in lung cancer patients: an evidence-based study
por: Rodríguez-Cano, Fernando, et al.
Publicado: (2023)

Cancer and SARS-CoV-2 Infection: A Third-Level Hospital Experience
por: Calvo, Virginia, et al.
Publicado: (2021)

Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
por: Palka, Magda, et al.
Publicado: (2017)

Clinical factors influencing long-term survival in a real-life cohort of early stage non-small-cell lung cancer patients in Spain
por: Torrente, Maria, et al.
Publicado: (2023)

EP06.01-017 Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
por: Garitaonaindía Díaz, Y., et al.
Publicado: (2022)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

1733P Real-world data: Cancer and SARS-CoV-2 infection
por: Nunez Garcia, B., et al.
Publicado: (2020)

PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy
por: Cruz-Bermúdez, Alberto, et al.
Publicado: (2017)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC
por: Agrawal, Vishesh, et al.
Publicado: (2017)

Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I–IIIA
por: Wallerek, Sandra, et al.
Publicado: (2015)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Robotic-assisted thoracoscopic surgery for clinically stage IIIA (c-N2) NSCLC—is it justified?
por: Weder, Walter, et al.
Publicado: (2021)

Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)

P31.03 The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain
por: Cudero, L., et al.
Publicado: (2021)

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers
por: Kilvaer, Thomas K., et al.
Publicado: (2015)

Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Dan, Aravot, et al.
Publicado: (2019)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients
por: Wang, Yukun, et al.
Publicado: (2023)

Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Correction to: Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity
por: Aravot, Dan, et al.
Publicado: (2019)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Patterns and outcome of unplanned care in lung cancer patients: an observational study in a medical oncology department
por: Sánchez, Juan C., et al.
Publicado: (2023)

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
por: Crandall, John P., et al.
Publicado: (2017)

The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study
por: Duan, Hongxia, et al.
Publicado: (2020)

P09.12 SARS- CoV2 Impact in a Spanish Lung Cancer Cohort?
por: Nunez-Garcia, B., et al.
Publicado: (2021)

Ionic liquids IIIA
por: Rogers, Robin D, et al.
Publicado: (2005)

Endostar in combination with postoperative adjuvant chemotherapy prolongs the disease free survival of stage IIIA NSCLC patients with high VEGF expression
por: Chen, Zhiwei, et al.
Publicado: (2017)

Preliminary Results of Robotic Lobectomy in Stage IIIA-N2 NSCLC after Induction Treatment: A Case Control Study
por: Casiraghi, Monica, et al.
Publicado: (2021)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC)
por: Hui, Zhenzhen, et al.
Publicado: (2022)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy
por: Chen, Yonghong, et al.
Publicado: (2018)

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study
por: Shang, Xiaoling, et al.
Publicado: (2018)

Effects of postoperative radiotherapy on cardiovascular-pulmonary disease mortality in patients with stage IIIA-N2 resected NSCLC: analysis of the SEER database
por: Wang, Xia, et al.
Publicado: (2021)

Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC
por: Brazel, Danielle, et al.
Publicado: (2022)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vaqihm8rr84nmp0qtspdda9tql